Welcome to our dedicated page for Kenvue SEC filings (Ticker: KVUE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kenvue Inc. filings document the public-company disclosures of a pure-play consumer health issuer with brands including Tylenol, Listerine, Johnson’s, Aveeno, Neutrogena and BAND-AID Brand. Its SEC record includes material-event reports, proxy and governance disclosures, shareholder voting matters, capital-structure information, operating and financial results, and consumer-health regulatory topics.
The company’s filings also cover executive officer appointments and compensatory arrangements, material definitive agreements, risk-factor disclosures and common-stock matters. Proxy materials and Form 8-K reports provide formal records of board governance, security-holder votes and other events affecting Kenvue’s corporate structure and reporting obligations.
Kenvue Inc. director Jeffrey C. Smith reported purchases of the company’s common stock through accounts managed by Starboard Value LP. On 12/11/2025, the Starboard Accounts bought 3,177,694 shares at a weighted-average price of $17.4318 per share, and on 12/12/2025 they bought 3,200,000 shares at a weighted-average price of $17.373 per share. Following these transactions, 27,307,632 Kenvue shares were beneficially owned by the Starboard Accounts and reported as indirectly owned by Smith. The filing notes that, as a managing member of Starboard, he may be deemed to beneficially own these securities for Section 16 purposes but disclaims beneficial ownership except to the extent of his pecuniary interest. Smith also holds 13,641.878 deferred share units, each representing one share of common stock to be delivered after his separation from service, including units credited as dividend equivalents.
Kenvue Inc. director Jeffrey C. Smith reported his latest beneficial ownership in the company’s stock. The filing shows indirect ownership of 20,929,938 shares of Kenvue common stock through Starboard Value LP-managed accounts. Smith also acquired 1,451 Deferred Share Units (DSUs) on 12/01/2025, which are a form of stock-denominated director compensation.
Each DSU represents the right to receive one share of Kenvue common stock, to be settled after Smith’s separation from service under the company’s deferred fee plan for directors. Following this grant, he directly holds 13,641.878 DSUs, while his indirect holdings through Starboard reflect his economic interest in accounts managed by that firm.
Kenvue Inc. director reports additional deferred share units
A director of Kenvue Inc. (KVUE) filed a Form 4 reporting the acquisition of 1,451 Deferred Share Units ("DSUs") on 12/01/2025 under the company's Amended and Restated Deferred Fee Plan for Directors. Each DSU represents the right to receive one share of Kenvue common stock, to be settled in shares after the director separates from service. Following this transaction, the director beneficially owns a total of 13,641.878 DSUs, which includes DSUs acquired as dividend equivalents.
Kenvue Inc.'s General Counsel reported equity transactions involving company stock on Form 4. On 12/01/2025, 4,378.21 restricted stock units were converted into the same number of common shares at an exercise price of $0, reflecting the vesting of previously granted equity awards. On the same date, 2,031 shares of common stock were withheld at a price of $17.22 per share to cover taxes due at vesting. After these transactions, the reporting person directly owned 28,839.324 shares of Kenvue common stock, including shares acquired through dividend reinvestment. The underlying award vests in three equal installments on 12/01/2024, 12/01/2025, and 12/01/2026, contingent on continued service.
Kenvue Inc. executive reports RSU vesting and share ownership update. A Group President for EMEA & LA exercised 1,779 restricted stock units into common stock on 12/01/2025 at an exercise price of $0, retaining all shares and paying related tax withholdings in cash. Following this transaction, the insider beneficially owns 58,095.03 shares of Kenvue common stock in direct form.
The Form 4 also shows 1,778.07 restricted stock units remaining beneficially owned after the reported transaction. The underlying RSU award is scheduled to vest in three equal installments on 12/01/2024, 12/01/2025, and 12/01/2026, conditioned on continued service. The filing notes that each unit corresponds on a 1‑for‑1 basis with Kenvue common stock and that the reported share balance includes amounts acquired through dividend reinvestment.
Kenvue Inc. Chief Operations Officer reported routine equity compensation activity. On 12/01/2025, the officer converted 2,775.95 restricted stock units into the same number of common shares at an exercise price of $0, reflecting vesting of prior awards. On the same date, 1,180 common shares were withheld at a price of $17.22 to cover taxes due upon RSU vesting. After these transactions, the officer directly owned 66,037.18 shares of Kenvue common stock and held 3,009.28 RSUs, which include units acquired through dividend reinvestment and an award that vests in three equal installments through 12/01/2026.
Kenvue Inc. director reported a routine insider transaction involving deferred equity compensation. On 12/01/2025, the director acquired 1,451 Deferred Share Units (DSUs), each representing the right to receive one share of Kenvue common stock. These DSUs reflect deferral of cash fees under Kenvue’s Amended and Restated Deferred Fee Plan for Directors and are to be settled in shares after the director separates from service. Following this transaction, the director beneficially owned 35,906.289 DSUs, a figure that includes amounts accumulated through dividend reinvestment.
Kenvue Inc. Chief People Officer Luani Alvarado converted 2,020.7800 Restricted Stock Units into an equal number of common shares on December 1, 2025. 731.0000 shares were withheld at $17.2200 per share to pay taxes on the vesting. She now holds 32,649.14 common shares directly and 2,222.2800 RSUs, which vest in three equal installments on 12/01/2024, 12/01/2025, and 12/01/2026.
Kenvue Inc. insider updates holdings after equity award vesting. The company’s Chief Scientific Officer reported the vesting and settlement of 1,538.75 Restricted Stock Units into an equal number of Kenvue common shares on 12/01/2025 at an exercise price of $0, reflecting equity compensation rather than an open‑market purchase.
To cover taxes due at vesting, 788 common shares were withheld and disposed of at a price of $17.22 per share. Following these transactions, the officer directly holds 44,879.51 shares of Kenvue common stock and 1,538.86 RSUs, which include units acquired through dividend reinvestment and are scheduled to vest in installments subject to continued service through the vesting dates.
Kenvue Inc. (KVUE) reported insider equity activity by its Chief People Officer on 11/18/2025. Restricted stock units converted into common shares on a one-for-one basis, including 309 and 123 units that became common stock. A matching 309 and 123 shares were withheld to cover FICA taxes arising from the officer being retirement eligible.
After these transactions, the officer directly beneficially owned 31,359.36 shares of Kenvue common stock. The filing also notes remaining restricted stock unit awards of 8,384.47 and 12,622.07 units, which vest in three equal installments on 03/05/2025, 03/05/2026, 03/05/2027 and on 03/10/2026, 03/10/2027, 03/10/2028, respectively, subject to continued service.